NCI10495
OPEN TO ACCRUAL
PH1 Study of DS-8201a in Combination with Neratinib in Solid Tumors with HER2 Alterations
UW22072
OPEN TO ACCRUAL
PH 1 Study CUE-102 in Subjects with HLA-A*0201 with WT1 Positive Recurrent/Metastatic Cancers
UW23126
OPEN TO ACCRUAL
A Phase 1a/1b Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
UW23151
OPEN TO ACCRUAL
Ph 1 Study of SynKIR-110, CAR-T Therapy in Pts w/ MSLN-Expressing OC, CCA, or Mesothelioma